AstraZeneca drug selumetinib fails in lung cancer study

LONDON, Aug 9 (Reuters) - AstraZeneca's cancer drug

pipeline suffered a setback on Tuesday when the experimental

drug selumetinib failed to meet its goal in a late-stage trial

for lung cancer.

Read more